Synovial sarcoma, X breakpoint 2B (SSX2B)

Synovial sarcoma, X breakpoint 2B (SSX2B) is a member of the SSX gene family encoding cancer-testis antigens (CTAs), which are typically expressed in germline tissues (primarily testis) but aberrantly upregulated in a wide variety of cancers, including synovial sarcoma, melanoma, and others[2][3]. SSX2B and its close homologue SSX2 function as chromatin-associated and possible transcriptional regulatory proteins, antagonizing Polycomb group (PcG) body-mediated gene repression and thereby altering local epigenetic landscape and gene expression[1][3]. In synovial sarcoma, chromosomal translocations result in fusion genes involving SSX family members (most commonly SSX1, SSX2, or SSX4), though direct oncogenic consequences are driven by these hybrid oncoproteins[3]. SSX2B can elicit spontaneous humoral and T-cell responses in cancer patients and is being investigated as a target for immunotherapeutic approaches, notably cancer vaccines and T-cell receptor–based strategies[2]. The primary safety consideration is antigen escape due to heterogeneous tumor expression, though the absence of detectable normal tissue expression outside the testis supports a favorable specificity profile for targeted immunotherapy[2][3].

Other names

Protein SSX2SSX2SSX2ACT5.2CT5.2bCancer/testis antigen 5.2Synovial sarcoma, X breakpoint 2Tumor antigen HOM-MEL-40Cancer/testis antigen family 5, member 2bHOM-MEL-40SSXprotein SSX2[2][3]

Immune-mediated cytotoxicity (peptide/epitope-based cancer vaccines or adoptive T-cell transfer targeting presented SSX2/SSX2B antigens in HLA context)[2]